skullcapflavone ii has been researched along with moracin c in 1 studies
| Studies (skullcapflavone ii) | Trials (skullcapflavone ii) | Recent Studies (post-2010) (skullcapflavone ii) | Studies (moracin c) | Trials (moracin c) | Recent Studies (post-2010) (moracin c) |
|---|---|---|---|---|---|
| 18 | 0 | 13 | 18 | 0 | 15 |
| Protein | Taxonomy | skullcapflavone ii (IC50) | moracin c (IC50) |
|---|---|---|---|
| Polyphenol oxidase 2 | Agaricus bisporus | 2.27 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 2.35 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 2.35 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Homo sapiens (human) | 1.21 | |
| Polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | 0.21 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, S; Xu, J; Xu, S; Zhu, Z | 1 |
1 review(s) available for skullcapflavone ii and moracin c
| Article | Year |
|---|---|
Small molecules as inhibitors of PCSK9: Current status and future challenges.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Enzyme Inhibitors; Humans; Hypercholesterolemia; PCSK9 Inhibitors | 2019 |